Related Experiment Video
Updated: Feb 16, 2026
06:35
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
7.6K
ABCG2 as a therapeutic target candidate for gout
Kyoko Fujita1, Kimiyoshi Ichida1
1a Department of Pathophysiology, School of Pharmacy , Tokyo University of Pharmacy and Life Sciences , Tokyo , Japan.
Expert Opinion on Therapeutic Targets
|December 22, 2017
Summary
Targeting ATP-binding cassette transporter G2 (ABCG2) shows promise for treating gout and hyperuricemia. Enhancing intestinal ABCG2 function could effectively promote uric acid excretion and prevent disease.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Background:
- Hyperuricemia, characterized by elevated serum uric acid, is the primary cause of gout, a common inflammatory arthritis.
- Management of gout and hyperuricemia necessitates control of serum uric acid levels.
- ATP-binding cassette transporter, sub-family G, member 2 (ABCG2) is a key urate transporter involved in renal and extra-renal excretion.
Purpose of the Study:
- To review the role of ABCG2 in uric acid regulation and its potential as a therapeutic target for gout.
- To examine recent findings on ABCG2 function, genetic factors, and drug effects.
- To explore strategies for modulating ABCG2 expression to treat hyperuricemia.
Main Methods:
- Literature review of studies on ABCG2 function, genetics, and therapeutic potential.
- Analysis of ABCG2's role in intestinal and renal urate excretion.
- Examination of methods to upregulate intestinal ABCG2 expression.
Main Results:
- ABCG2 dysfunction contributes to hyperuricemia by impairing extra-renal urate excretion, primarily in the intestine.
- Genetic variations and molecular structure influence ABCG2 function.
- Upregulating intestinal ABCG2 presents a potential therapeutic strategy.
Conclusions:
- ABCG2 is a promising therapeutic target for gout and hyperuricemia due to its role in extra-renal urate excretion.
- Manipulating ABCG2 expression and localization can effectively promote uric acid excretion.
- Targeting ABCG2 offers a novel approach to gout management.
More Related Videos
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:09GPCRs Regulate Adenylyl Cylase Activity
7.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.7K
01:26Targets for Drug Action: Overview
10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.2K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.2K
01:15G Protein-coupled Receptors
17.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
17.9K